Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence

Nikita Sushentsev; Gregory Hamm; Jack Richings; Mary A McLean; Ines Horvat Menih; Vinay Ayyappan; Ian G Mills; Anne Y Warren; Vincent J Gnanapragasam; Simon T Barry; Richard J A Goodwin; Ferdia A Gallagher; Tristan Barrett

doi:10.1073/pnas.2312261120

Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence

Nikita Sushentsev, Gregory Hamm, Jack Richings, Mary A McLean, Ines Horvat Menih, Vinay Ayyappan, Ian G Mills, Anne Y Warren, Vincent J Gnanapragasam, Simon T Barry, Richard J A Goodwin, Ferdia A Gallagher, Tristan Barrett

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

30 Downloads (Pure)

Abstract

While radical prostatectomy remains the mainstay of prostate cancer (PCa) treatment, 20 to 40% of patients develop postsurgical biochemical recurrence (BCR). A particularly challenging clinical cohort includes patients with intermediate-risk disease whose risk stratification would benefit from advanced approaches that complement standard-of-care diagnostic tools. Here, we show that imaging tumor lactate using hyperpolarized 13C MRI and spatial metabolomics identifies BCR-positive patients in two prospective intermediate-risk surgical cohorts. Supported by spatially resolved tissue analysis of established glycolytic biomarkers, this study provides the rationale for multicenter trials of tumor metabolic imaging as an auxiliary tool to support PCa treatment decision-making.

Original language	English
Article number	e2312261120
Number of pages	3
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	120
Issue number	49
Early online date	27 Nov 2023
DOIs	https://doi.org/10.1073/pnas.2312261120
Publication status	Published - 05 Dec 2023

Keywords

Male
Humans
Prostate-Specific Antigen/analysis
Lactic Acid
Prospective Studies
Prostatic Neoplasms/diagnostic imaging
Prostate/pathology
Prostatectomy/methods
Neoplasm Recurrence, Local/diagnostic imaging
Retrospective Studies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1073/pnas.2312261120Licence: CC BY

Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence
Copyright 2023 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 4.76 MBLicence: CC BY

Cite this

Sushentsev, N., Hamm, G., Richings, J., McLean, M. A., Menih, I. H., Ayyappan, V., Mills, I. G., Warren, A. Y., Gnanapragasam, V. J., Barry, S. T., Goodwin, R. J. A., Gallagher, F. A., & Barrett, T. (2023). Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence. Proceedings of the National Academy of Sciences of the United States of America, 120(49), Article e2312261120. https://doi.org/10.1073/pnas.2312261120

@article{045b8c8d2b774858ab13fc5c173c9a41,

title = "Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence",

abstract = "While radical prostatectomy remains the mainstay of prostate cancer (PCa) treatment, 20 to 40% of patients develop postsurgical biochemical recurrence (BCR). A particularly challenging clinical cohort includes patients with intermediate-risk disease whose risk stratification would benefit from advanced approaches that complement standard-of-care diagnostic tools. Here, we show that imaging tumor lactate using hyperpolarized 13C MRI and spatial metabolomics identifies BCR-positive patients in two prospective intermediate-risk surgical cohorts. Supported by spatially resolved tissue analysis of established glycolytic biomarkers, this study provides the rationale for multicenter trials of tumor metabolic imaging as an auxiliary tool to support PCa treatment decision-making.",

keywords = "Male, Humans, Prostate-Specific Antigen/analysis, Lactic Acid, Prospective Studies, Prostatic Neoplasms/diagnostic imaging, Prostate/pathology, Prostatectomy/methods, Neoplasm Recurrence, Local/diagnostic imaging, Retrospective Studies",

author = "Nikita Sushentsev and Gregory Hamm and Jack Richings and McLean, {Mary A} and Menih, {Ines Horvat} and Vinay Ayyappan and Mills, {Ian G} and Warren, {Anne Y} and Gnanapragasam, {Vincent J} and Barry, {Simon T} and Goodwin, {Richard J A} and Gallagher, {Ferdia A} and Tristan Barrett",

year = "2023",

month = dec,

day = "5",

doi = "10.1073/pnas.2312261120",

language = "English",

volume = "120",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "49",

}

Sushentsev, N, Hamm, G, Richings, J, McLean, MA, Menih, IH, Ayyappan, V, Mills, IG, Warren, AY, Gnanapragasam, VJ, Barry, ST, Goodwin, RJA, Gallagher, FA & Barrett, T 2023, 'Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence', Proceedings of the National Academy of Sciences of the United States of America, vol. 120, no. 49, e2312261120. https://doi.org/10.1073/pnas.2312261120

Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence. / Sushentsev, Nikita; Hamm, Gregory; Richings, Jack et al.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, No. 49, e2312261120, 05.12.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence

AU - Sushentsev, Nikita

AU - Hamm, Gregory

AU - Richings, Jack

AU - McLean, Mary A

AU - Menih, Ines Horvat

AU - Ayyappan, Vinay

AU - Mills, Ian G

AU - Warren, Anne Y

AU - Gnanapragasam, Vincent J

AU - Barry, Simon T

AU - Goodwin, Richard J A

AU - Gallagher, Ferdia A

AU - Barrett, Tristan

PY - 2023/12/5

Y1 - 2023/12/5

N2 - While radical prostatectomy remains the mainstay of prostate cancer (PCa) treatment, 20 to 40% of patients develop postsurgical biochemical recurrence (BCR). A particularly challenging clinical cohort includes patients with intermediate-risk disease whose risk stratification would benefit from advanced approaches that complement standard-of-care diagnostic tools. Here, we show that imaging tumor lactate using hyperpolarized 13C MRI and spatial metabolomics identifies BCR-positive patients in two prospective intermediate-risk surgical cohorts. Supported by spatially resolved tissue analysis of established glycolytic biomarkers, this study provides the rationale for multicenter trials of tumor metabolic imaging as an auxiliary tool to support PCa treatment decision-making.

AB - While radical prostatectomy remains the mainstay of prostate cancer (PCa) treatment, 20 to 40% of patients develop postsurgical biochemical recurrence (BCR). A particularly challenging clinical cohort includes patients with intermediate-risk disease whose risk stratification would benefit from advanced approaches that complement standard-of-care diagnostic tools. Here, we show that imaging tumor lactate using hyperpolarized 13C MRI and spatial metabolomics identifies BCR-positive patients in two prospective intermediate-risk surgical cohorts. Supported by spatially resolved tissue analysis of established glycolytic biomarkers, this study provides the rationale for multicenter trials of tumor metabolic imaging as an auxiliary tool to support PCa treatment decision-making.

KW - Male

KW - Humans

KW - Prostate-Specific Antigen/analysis

KW - Lactic Acid

KW - Prospective Studies

KW - Prostatic Neoplasms/diagnostic imaging

KW - Prostate/pathology

KW - Prostatectomy/methods

KW - Neoplasm Recurrence, Local/diagnostic imaging

KW - Retrospective Studies

U2 - 10.1073/pnas.2312261120

DO - 10.1073/pnas.2312261120

M3 - Article

C2 - 38011568

SN - 0027-8424

VL - 120

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 49

M1 - e2312261120

ER -

Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this